Leo Timoshev

“Just wanted to ask on the commercial side, at least clinically, you guys have always been planning for success. I guess to what extent does that extend to the sales force sizing commercially?”

“I wanted to pivot maybe to the the commercial side of A plus F, really appreciated the color on sort of how you see the commercial strategy evolving. But I guess I'm curious if you could provide more details on how you'll actually affect those changes.”

“I want to stick with the franchise approach by 2030 that you've been talking about. I mean, you've mentioned CRC. I wanted to focus on NETS and how you're thinking about the franchise there in the future.”

“I'm sure I'll ask two on the pipeline in terms of broad strategy. I guess first, you guys have explored allo approaches, gamma delta, NK, in vivo. I guess how are you thinking about what the winner is going to be?”

“I wanted to ask a little bit on RMO55 and that class of molecules. I guess, does this address secondary mutations or does it really only work directly on RAS mutations themselves And I guess, said another way, are you seeing this line option, or can this be something that...”